<DOC>
	<DOCNO>NCT00138983</DOCNO>
	<brief_summary>The purpose study determine wich treatment effective prevention glucocorticoid-induced osteoporosis patient rheumatic disease . The STOP-study : randomize placebo control trial alendronate versus alfacalcidol .</brief_summary>
	<brief_title>Prevention Glucocorticoid-Induced Osteoporosis Rheumatic Diseases : Alendronate Versus Alfacalcidol .</brief_title>
	<detailed_description>Treatment glucocorticoid ( GCs ) associate bone loss initiate already early therapy , cause increase ( vertebral ) fracture risk . Bone loss cause inhibition bone formation GCs . Active vitamin D analogue like alfacalcidol directly stimulate osteoblast lead increase bone formation . Bisphosphonates like alendronate induce apoptosis osteoclasts lead inhibition bone resorption . We perform randomize , double-placebo , double-blind clinical trial 18 month duration patient rheumatic disease , start GCs dosage 7.5 mg prednisone equivalent daily high . Two hundred one patient allocate receive either alendronate 10 mg alfacalcidol-placebo daily alfacalcidol 1 microgram alendronate-placebo daily . Primary outcome change bone mineral density lumbar spine 18 month , secondary outcome incidence ( symptomatic ) morphometric vertebral deformity .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Patients rheumatic disease . Starting treatment glucocorticoid dosage 7.5 mg prednisone equivalent daily high . All ethnic group race . Glucocorticoid treatment past 12 month ( except 12 week precede study ) Primary hyperparathyroidism , hyperthyroidism hypothyroidism last year Metabolic bone disease Creatinine clearance &lt; 50 ml/min Documented hypercalcemia hypercalciuria , nephrolithiasis last 5 year Pregnancy lactation Treatment last 12 month hormonereplacement therapy Anabolic steroid , calcitonin , active vitamin D3 analogue , fluoride bisphosphonates .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>glucocorticoid-induced osteoporosis</keyword>
	<keyword>rheumatic disease</keyword>
	<keyword>prevention</keyword>
	<keyword>randomize double-blind , double placebo control trial</keyword>
	<keyword>alendronate versus alfacalcidol</keyword>
</DOC>